Goldman Sachs raised the firm’s price target on Amneal Pharmaceuticals (AMRX) to $17 from $15 and keeps a Buy rating on the shares. Amneal Pharmaceuticals shares pulled back slightly after Q4 EPS due to softer GRx performance and FY26 topline guidance from the distribution segment, though the strong FY26 EBITDA outlook supports a long-term growth thesis that remains intact, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRX:
- Amneal Pharmaceuticals price target raised to $17 from $15 at Truist
- Truist ups Amneal Pharmaceuticals price target, says pullback great entry point
- Amneal Pharmaceuticals: Portfolio Shift to High-Margin Brands and Biosimilars Supports Buy Rating and Upside to $17 Target
- Amneal Posts Strong Q4 Results and Raises 2026 Outlook
- Options Volatility and Implied Earnings Moves Today, February 27, 2026